The first human research shows promising results

A transparent electron micrograph of Marburg virus particles (blue) collected from the superior of infected Vero E6 cells. An image that was captured at his NIAID integrated research facility in Fort Detric, Maryland, and emphasized color. Credit: NIAID

According to a newly published paper, vaccines for Marburg virus (MARV) were safe, inducing an immune response in small first human clinical trials. LancetThis vaccine was developed by a researcher of the National Institute of Institute of National Allergy (NIAID). National Institutes of HealthSomeday, it may be an important tool to respond to the generation of Marburgivirus.

In this first person’s first phase study, we tested an MARV vaccine candidate known as a CAD3-Marburg developed at the NIAID vaccine research center (VRC). This vaccine uses a modified chimpanze adenovirus called CAD3. CAD3 becomes unable to replicate or infect cells, presents the sugar protein on the surface of the MARV, and induces an immune response to the virus. CAD3 vaccine platforms showed good safety profiles in the previous clinical trials when used in the Ebola virus and Sudan virus vaccine developed by VRC.

A scanned electron micrographic photo of the Marburg virus particles (blue) that germinates on the surface of infected Vero E6 cells (orange). An image that was captured at his NIAID integrated research facility in Fort Detric, Maryland, and emphasized color. Credit: NIAID

MARV, the same family of the family as Ebola virus, causes rapidly advanced thermal diseases, and is shocked and died in most of the infected individuals. Many scientists believe that the occurrence of her MARV disease in humans begins when the virus jumps from a major animal host. The symptoms of MARV disease are similar to Ebola virus disease, such as fever, headache, chills, rash, abdominal pain, vomiting, and diarrhea. As the disease progresses, patients may suffer from multiple organ dysfunction, delirium, and severe bleeding from gastrointestinal or other parts, and may die. Except for support therapy, there are no approved vaccines or specific treatments that can be used for MARV disease. Several vaccines have been tested earlier, but have been very effective and have not proved to provide permanent protection. Africa in Africa, which requires the most of the Malburg disease vaccine. In the region, a single -time vaccine that can protect in vacciners for a long time will be an important part to calm the outbreak.

In this study, 40 healthy adult volunteers were registered at the Walter Lead Army Research Institute in Silver Spring, Maryland. They are low -dose vaccines (1 × 10)^Ten Particle unit) or higher dose (1 × 10)¹¹ Particle unit). For safety, the volunteers were registered in the dosage plan. The three participants received a lower dose. After that, when his serious side effects were no longer seen in the first seven days, the exam proceeded to registration of the remaining 17 volunteers. The same procedure was also used in the high dose group. Volunteers were monitored the harmful reactions to the clinical trial vaccine, and he was regularly evaluated for 48 weeks to track the immune reaction.

The result of the safety of the exam was encouraging. There were no serious adverse events, and the vaccine had good ninja. One of the high -dose group participants generated heat after vaccination, but subsided the next day. In addition, the clinical test seemed to induce her powerful and long -term immunity to her marv glycoprotein. 95 % of the test participants showed a powerful antibody reaction after vaccination, and 70 % maintained the reaction for more than 48 weeks.

Ghana, Kenya, Uganda, and the United States are planning to conduct further tests for CAD3-Marburg vaccines. If additional data supports the promising results seen in the first phase test, the CAD3-Malburg virus vaccine may be used in an emergency response to MARV occurrence someday.

See: “Chimpanzie adenovirus 3 type vector Malburg virus (CAD3-Marburg) Vaccine’s safety, ninja, and immunity, and immunity: Human first, 1st phase, dose increase test Melinda J. Hummer Medicine. Dr. Catherine V Hauser. Dr. Amelia R. Hoffstetter. ANA M Ortega-Villa, Dr. Christine Lee Medical Science. Dr. Christine Leau Medical. Charla and Ruis, MS. Garina V. Yamushichikov, MS. Dr. Somia Hickman, Academic, Jack N. Hatter Medicine. Dr. Paul T. Scott Medical Science. Page e. Wataman Medical Doctor 。 Millet F. Amare, MBA. Victoria Kioko, MPH. Casey Steem, MPH. Kayvon Modjarrad, MD. Dr. Maccori Macquerley. Merlin L. Rob, MD; Martin R. R. Gaudin Sky Medicine 。 Ingelise J Gordon, RN; Lasonji a Holman, FNP; Dr. La Lisa Strom, MPH. Dr. Josephin H. Cox. Dr. Josephin H. Cox. DAPHNE A STANLEY, MS. 。 Tamar Murray、理学士。 Caitlyn NM Dulan、MS; ルース・ヒューネグナウ博士。 Sandeep R Narpala、MS。 Phillip A Swanson II、PhD。 Manjula Basappa、BS; ジャガダ・ティライナサン、理学士。 Marcelino Padilla、BS; Britta Flach Dr.. Sarah Okonnell, MS. Dr. Olga Trofimenko Medical Science. Patricia Morgan, MS. Dr. Emily E. Coating. Dr. Jason G Gal. Dr. Adrian B. Makder Mot. Dr. John R. Mascola Medical Science. Dr. Aurely Professional Knight. Dr. Nancy J. Sullivan. Julie Ake, MD; Julie E Ledgerwood, DO and RV 507 Survey Team, January 2023 28th day, Lancet.
Doi: 10.1016/S0140-6736 (22) 02400-X

Funds: NIH/National Infection Research Institute